<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001137883</identifier>
        </entity>
        <period>
            <startDate>2026-05-18</startDate>
            <endDate>2026-05-18</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001137883</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-18</startDate>
            <endDate>2026-05-18</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-168">S-8</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-169">S-8</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-170">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-171">0001137883</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-172">BRAINSTORM CELL THERAPEUTICS INC.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-175">false</ffd:PrevslyPdFlg>
    <ffd:FormTp contextRef="rc" id="ixv-200">S-8</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-201">BRAINSTORM CELL THERAPEUTICS INC.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-202">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-203">Common Stock, $0.00005 par value per share</ffd:OfferingSctyTitl>
    <ffd:Rule457aFlg contextRef="offrl_1" id="ixv-204">true</ffd:Rule457aFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-205"
      unitRef="Shares">5500000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="3"
      id="ixv-206"
      unitRef="USD">0.695</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="2"
      id="ixv-207"
      unitRef="USD">3822500.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="7"
      id="ixv-208"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="2"
      id="ixv-209"
      unitRef="USD">527.89</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="2" id="ixv-210" unitRef="USD">3822500.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="2" id="ixv-211" unitRef="USD">527.89</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="2" id="ixv-212" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="2" id="ixv-213" unitRef="USD">527.89</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-214">a) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, $0.00005 par value per share (the "Common Stock") of Brainstorm Cell Therapeutics Inc. (the "Registrant") that become issuable under the Registrant's 2014 Stock Incentive Plan and 2014 Global Share Option Plan, as amended (the "Plans"), by reason of any stock dividend, stock split, recapitalization or any other similar transactions.
 
b) Represents an increase of 5,500,000 shares of Common Stock available for issuance under the Plans.
 
c) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on $0.695, the average of the high and low sale prices of the Common Stock as reported on the OTCQB on May 17, 2026 (such date being within five business days of the date that this Registration Statement was filed with the Commission).</ffd:OfferingNote>
</xbrl>
